Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Motor nerve conduction measurements

From: Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: A randomized double-blind placebo controlled trial

  group Pre-chemotherapy Post-chemotherapy* p-value #
Tibial nerve     
DML(ms) Omega 3 16.53 (1.95) 17.59 (2.21) .870
  Placebo 17.00 (2.16) 17.80 (3.10)  
a-CMAP(mV) Omega 3 10.00 (5.18) 11.18 (6.35) .149
  Placebo 11.38 (6.08) 10.68 (5.80)  
MCV(m/s) Omega 3 46.38 (3.67) 45.16 (4.24) .359
  Placebo 46.24 (5.08) 46.03 (6.65)  
Peroneal nerve     
DML(ms) Omega 3 14.16 (1.80) 14.97 (2.53) .209
  Placebo 14.85 (3.18) 14.91 (2.37)  
a-CMAP(mV) Omega 3 6.20 (6.68) 4.43 (3.26) .549
  Placebo 5.51 (3.41) 3.83 (3.15)  
MCV(m/s) Omega 3 46.13 (3.32) 45.87 (4.75) .106
  Placebo 46.46 (5.24) 42.38 (9.90)  
Ulnar nerve     
DML(ms) Omega 3 9.48 (.74) 9.67 (.86) .439
  Placebo 9.67 (.98) 9.60 (1.29)  
a-CMAP(mV) Omega 3 17.29 (12.95) 14.25 (3.79) .256
  Placebo 13.80 (3.53) 13.29 (4.73)  
MCV(m/s) Omega 3 57.30 (5.18) 55.82 (6.35) .706
  Placebo 55.80 (4.90) 53.19 (7.29)  
  1. DML, distal motor latency; a-CMAP, amplitude of compound muscle action potential; MCV, motor conduction velocity.
  2. * One month after the cessation of chemotherapy.
  3. # p value is reported based on the analysis of covariance.